VL 2397

Drug Profile

VL 2397

Alternative Names: ASP-2397; VL-2397

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Vical
  • Class Anti-infectives; Antifungals; Macrocyclic compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Aspergillosis

Most Recent Events

  • 05 Jun 2017 Pharmacodynamics data from a preclinical trial in Candidiasis presented at the American Society of Microbiology Microbe 2017 meeting (ASM-2017)
  • 05 Jun 2017 Pharmacokinetic and adverse events data from a first-in-human phase I in Aspergillosis (In volunteers) presented at the American Society of Microbiology Microbe 2017 meeting (ASM-2017)
  • 10 Mar 2017 Vical completes a phase I trial in Aspergillosis (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top